论文部分内容阅读
目的探讨提高对急性巨核细胞白血病变为首发的慢性粒细胞白血病患者的细胞遗传学、免疫表型和临床特点认识的措施。方法对患者进行骨髓形态学、免疫学和细胞遗传学检查,并对其治疗效果进行分析。结果该患者经常规化疗未获缓解,建议口服格列卫治疗,因经济条件拒绝。结论急性巨核细胞白血病变为首发的慢性粒细胞白血病比较少见,伊马替尼能够使部分慢性粒细胞急变,使Philadelphia染色体阳性的急性巨核细胞白血病取得完全血液学缓解和细胞遗传学缓解。但目前伊马替尼仍较昂贵,限制了其在临床上广泛及长期的应用,若联合化疗方案,可能减少伊马替尼用量,并延长缓解期。
Objective To explore the measures to improve the understanding of cytogenetics, immunophenotypes and clinical features of patients with acute myelocytic leukemia (CML) which is the first onset of chronic myeloid leukemia. Methods The patients were examined by morphology, immunology and cytogenetics, and their therapeutic effects were analyzed. Results The patient was not relieved by conventional chemotherapy, oral Gleevec treatment is recommended, due to economic conditions refused. Conclusions Acute myelocytic leukemia is the first chronic myelogenous leukemia. Imatinib can make part of chronic myeloid leukemia acutely and make complete hematological remission and cytogenetic remission of Philadelphia chromosome positive acute megakaryocyte leukemia. However, the current imatinib is still more expensive, limiting its widespread and long-term clinical application, if combined with chemotherapy may reduce the amount of imatinib and prolong the remission.